At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GIAll Cohorts followed to 9 months have maintained clinically meaningful improvements in tissue health as measured by EoE Histological Scoring System (“EoEHSS”)No Serious Adverse Events (“SAE”) or any events of oral or gastrointestinal candidiasis have been reported to date in the entire trial VICTORIA, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceutica ...